

Guillaume Moulis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2372249/publications.pdf>

Version: 2024-02-01

91
papers

2,404
citations

257101

24
h-index

233125

45
g-index

119
all docs

119
docs citations

119
times ranked

3187
citing authors

#	ARTICLE	IF	CITATIONS
1	French health insurance databases: What interest for medical research?. <i>Revue De Medecine Interne</i> , 2015, 36, 411-417.	0.6	273
2	Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. <i>Blood</i> , 2014, 124, 3308-3315.	0.6	248
3	Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. <i>British Journal of Dermatology</i> , 2016, 175, 296-301.	1.4	153
4	Serious and Non-Serious Infections in Non-Splenectomized Adults Treated for Persistent or Chronic Primary Immune Thrombocytopenia: Effect of Treatments and Protection of Vaccines. Results of the French Nationwide Faith Study. <i>Blood</i> , 2015, 126, 9-9.	0.6	110
5	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. <i>Blood</i> , 2016, 128, 1625-1630.	0.6	78
6	Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 616-624.	1.0	74
7	Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1830-1842.	1.9	71
8	Cancer Risk of Anti-TNF- α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses. <i>PLoS ONE</i> , 2012, 7, e48991.	1.1	68
9	Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. <i>British Journal of Haematology</i> , 2020, 190, e224-e229.	1.2	68
10	Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. <i>American Journal of Hematology</i> , 2017, 92, 493-500.	2.0	67
11	Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e276-e279.	1.2	54
12	Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2016, 15, 203-209.	2.5	50
13	Exposure to Atropinic Drugs and Frailty Status. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 253-257.	1.2	47
14	Searching for a Polypharmacy Threshold Associated With Frailty. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 259-261.	1.2	44
15	Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. <i>American Journal of Hematology</i> , 2014, 89, 41-46.	2.0	39
16	Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience. <i>Rheumatology</i> , 2015, 54, 1852-1857.	0.9	38
17	Trends of reporting of "serious" vs "non-serious" adverse drug reactions over time: a study in the French Pharmacovigilance Database. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 201-204.	1.1	33
18	May anakinra be used earlier in adult onset Still disease?. <i>Clinical Rheumatology</i> , 2010, 29, 1199-1200.	1.0	31

#	ARTICLE	IF	CITATIONS
19	Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®. <i>Drug Safety</i> , 2015, 38, 1179-1186.	1.4	30
20	Drug-induced immune thrombocytopenia: A descriptive survey in the French Pharmacovigilance database. <i>Platelets</i> , 2012, 23, 490-494.	1.1	29
21	Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French Pharmacovigilance assessment. <i>European Journal of Internal Medicine</i> , 2014, 25, 777-780.	1.0	29
22	Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. <i>American Journal of Hematology</i> , 2015, 90, 301-305.	2.0	29
23	Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database. <i>Lupus</i> , 2012, 21, 885-889.	0.8	28
24	Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 785-789.	0.9	28
25	Acquired factor VIII haemophilia following influenza vaccination. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1069-1070.	0.8	26
26	Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. <i>Rheumatology</i> , 2014, 53, 1465-1469.	0.9	26
27	Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - Results from two nationwide cohorts. <i>Thrombosis Research</i> , 2019, 178, 124-131.	0.8	23
28	Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0142217.	1.1	23
29	Positive predictive values of peripheral arterial and venous thrombosis codes in French hospital database. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 108-113.	1.0	22
30	Biologics in relapsing polycondritis: a case series. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 937-9.	0.4	22
31	Pharmacoepidemiology of Immune Thrombocytopenia: Protocols of FAITH and CARMEN Studies. <i>Therapie</i> , 2014, 69, 437-448.	0.6	20
32	Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. <i>American Journal of Hematology</i> , 2016, 91, E499-E501.	2.0	20
33	Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2021, 195, 703-705.	1.2	20
34	Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 785-791.	1.9	19
35	Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 578-586.	0.9	18
36	Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database. <i>European Journal of Haematology</i> , 2017, 99, 344-349.	1.1	18

#	ARTICLE	IF	CITATIONS
37	Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. <i>Autoimmunity Reviews</i> , 2015, 14, 168-173.	2.5	17
38	Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 194-203.	1.0	17
39	Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Haematologica</i> , 2021, 106, 1414-1422.	1.7	17
40	Cryofibrinogenemia: A Marker of Severity of Cryoglobulinemic Vasculitis. <i>American Journal of Medicine</i> , 2015, 128, 916-921.	0.6	16
41	Positive predictive value of hospital discharge diagnosis code to identify immunoglobulin A vasculitis in France: A validation study. <i>European Journal of Internal Medicine</i> , 2017, 43, e18-e19.	1.0	15
42	Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 162-171.	1.0	14
43	Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease. <i>Blood</i> , 2022, 139, 3771-3777.	0.6	14
44	Very late relapse of dapsone-induced methaemoglobinemia. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 645-646.	0.8	12
45	De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring. <i>Blood</i> , 2022, 139, 2561-2565.	0.6	12
46	Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 314-319.	0.9	11
47	Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database. <i>European Journal of Internal Medicine</i> , 2016, 32, e21-e22.	1.0	11
48	High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. <i>American Journal of Hematology</i> , 2021, 96, E43-E46.	2.0	11
49	Epidemiology of autoimmune hemolytic anemia: A nationwide population-based study in France. <i>American Journal of Hematology</i> , 2021, 96, E291-E293.	2.0	10
50	Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1521-1522.	1.9	9
51	Early use of anakinra in adult-onset Still's disease myocarditis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 511-512.	0.6	9
52	Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry. <i>Blood Advances</i> , 2020, 4, 1974-1977.	2.5	9
53	Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study. <i>British Journal of Haematology</i> , 2021, 195, 456-465.	1.2	9
54	Assessment of the Accuracy of Using ICD-10 Codes to Identify Systemic Sclerosis. <i>Clinical Epidemiology</i> , 2020, Volume 12, 1355-1359.	1.5	9

#	ARTICLE	IF	CITATIONS
55	Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMENâ€France Registry. <i>British Journal of Haematology</i> , 2022, 196, 1262-1270.	1.2	9
56	Validation of giant cell arteritis diagnosis code in the French hospital electronic database. <i>European Journal of Internal Medicine</i> , 2019, 60, e16-e17.	1.0	8
57	Eltrombopag in adult patients with immune thrombocytopenia in the realâ€world in France, including offâ€label use before 6 months of disease duration: The multicenter, prospective <sc>ELEXTRA</sc> study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	8
58	Severe neonatal hypercalcemia related to maternal exposure to nutritional supplement containing Spirulina. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 221-222.	0.8	7
59	Prevalence of pneumococcal vaccination in adult immune thrombocytopenia patients exposed to rituximab or to splenectomy. <i>European Journal of Haematology</i> , 2013, 90, 438-439.	1.1	7
60	Seasonal variations of incident primary immune thrombocytopenia in adults: An ecological study. <i>European Journal of Internal Medicine</i> , 2017, 37, e26-e28.	1.0	7
61	Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis. <i>Journal of Rheumatology</i> , 2018, 45, 1541-1548.	1.0	7
62	Cross-national health care database utilization between Spain and France: results from the EPICHRONIC study assessing the prevalence of type 2 diabetes mellitus. <i>Clinical Epidemiology</i> , 2018, Volume 10, 863-874.	1.5	7
63	Validation of hemolytic anemia discharge diagnosis codes in the French hospital database. <i>European Journal of Internal Medicine</i> , 2020, 79, 136-138.	1.0	7
64	Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19. <i>BMC Pharmacology & Toxicology</i> , 2021, 22, 14.	1.0	7
65	Imaging in Erdheim-Chester disease: classic features and new insights. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 410-4.	0.4	7
66	Scrofula, the kingâ€™s evil: Figure 1:. <i>Cmaj</i> , 2012, 184, 1061-1061.	0.9	6
67	Positivity rate of systematic bone marrow smear in patients over 60 years old with newly diagnosed immune thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 2136-2138.	2.5	5
68	Risk of Immune Thrombocytopenia After Influenza Vaccine. <i>JAMA Internal Medicine</i> , 2022, 182, 444.	2.6	5
69	Mortality Rates Among Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors: Comment on the Article by Simard et al. <i>Arthritis and Rheumatism</i> , 2013, 65, 1670-1671.	6.7	4
70	Effect of pregnancy in women with a history of primary immune thrombocytopenia considered as cured. <i>European Journal of Internal Medicine</i> , 2017, 46, e15-e16.	1.0	4
71	Prevalence of thrombocytopenia and thrombocytosis upon acute hospital admission to internal medicine units. A cross-sectional study in Denmark. <i>European Journal of Internal Medicine</i> , 2018, 57, e34-e37.	1.0	4
72	Antithrombotic therapy management in patients with inherited bleeding disorders and coronary artery disease: A singleâ€centre experience. <i>Haemophilia</i> , 2020, 26, e34-e37.	1.0	4

#	ARTICLE	IF	CITATIONS
73	Cardiovascular risk factors in immune thrombocytopenia adults: Results from the CARMEN registry. American Journal of Hematology, 2018, 93, E181-E184.	2.0	3
74	<p><p>Platelet Count within the Normal Range at Hospital Admission is Associated with Mortality in Patients with Community-Acquired Pneumonia</p></p>. Clinical Epidemiology, 2020, Volume 12, 711-716.	1.5	3
75	Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives. Fundamental and Clinical Pharmacology, 2022, 36, 16-34.	1.0	3
76	Validation of Discharge Diagnosis of Sickle Cell Disease Vaso-Occlusive Episodes in the French Hospital Electronic Database. Clinical Epidemiology, 2021, Volume 13, 717-720.	1.5	3
77	Correspondence on "Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study"™. Annals of the Rheumatic Diseases, 2023, 82, e95-e95.	0.5	3
78	Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort. Blood, 2015, 126, 3473-3473.	0.6	3
79	Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia. Platelets, 2022, 33, 1153-1158.	1.1	3
80	Cryofibrinogenemia and risk of cancer in cryoglobulinemic patients without vasculitis criteria. European Journal of Internal Medicine, 2016, 28, e10-e12.	1.0	2
81	Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (<sc>ITP</sc>). European Journal of Haematology, 2018, 100, 412-418.	1.1	2
82	Risk Factors of Thrombosis in Adults with Primary Immune Thrombocytopenia. a French Nationwide Cohort Study. Blood, 2018, 132, 3745-3745.	0.6	2
83	Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (<sc>ERCI</sc>) network. British Journal of Haematology, 2022, 197, 633-638.	1.2	2
84	Reply to the commentary by Onuigbo on the article "Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins. A case-control study". Pharmacoepidemiology and Drug Safety, 2012, 21, 900-901.	0.9	1
85	A New Tool to Assess the Epidemiology of Immune Thrombocytopenia: The Nordic Country Patient Registry for Romiplostim. EClinicalMedicine, 2019, 14, 11-12.	3.2	1
86	Platelet counts of adults upon acute hospital admission to internal medicine units are a predictor of mortality. Annals of Hematology, 2020, 99, 451-457.	0.8	1
87	Immune Thrombocytopenia in Very Elderly Patients: Particularities in Presentation and Management. Results from the Multicenter Prospective Carmen-France Registry. Blood, 2019, 134, 1091-1091.	0.6	1
88	Validation of an Algorithm Identifying Incident Primary Immune Thrombocytopenia in the French National Health Insurance Database. Blood, 2016, 128, 4764-4764.	0.6	1
89	Adolescents and Young Adults with Immune Thrombocytopenia (ITP): A Project of the Carmen-France and Parc-ITP Registry. Blood, 2021, 138, 2079-2079.	0.6	1
90	No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study. British Journal of Haematology, 2020, 189, e137-e140.	1.2	0

#	ARTICLE	IF	CITATIONS
91	Platelet Count upon Acute Hospital Admission to Internal Medicine Units Is a Predictor of Mortality in Adults: A Danish Cohort Study. <i>Blood</i> , 2018, 132, 3578-3578.	0.6	0